1987;76:125 34. 371. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary- artery stents. N Engl J Med. 1996;334:1084 9. 372. Steinhubl SR, Ellis SG, Wolski K, et al. Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse car- diac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial. Circulation. 2001;103:1403 9. 373. Steinhubl DR, Deal DB. Optimal duration of pretreatment with clopido- grel prior to PCI: data from the CREDO trial. Circulation. 2003;108(suppl I):I1742. Abstract. 374. Gurbel PA, Bliden KP, Zaman KA, et al. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation. 2005:111:1153 9. 375. Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pre- treatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI- CLARITY study. JAMA. 2005;294:1224 32. 376. von Beckerath N, Taubert D, Pogatsa-Murray G, et al.Absorption, metab- olization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation. 2005;112:2946 50. 377. Siller-Matula JM, Huber K, Christ G, et al. Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Heart. 2011;97:98 105. 378. Mangiacapra F, Muller O, Ntalianis A, et al. Comparison of 600 versus 300-mg clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary coronary angioplasty. Am J Cardiol. 2010;106:1208 11. 379. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose hepa- rin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med. 